DrugCite
Search

TAREG

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Tareg Adverse Events Reported to the FDA Over Time

How are Tareg adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Tareg, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Tareg is flagged as the suspect drug causing the adverse event.

Most Common Tareg Adverse Events Reported to the FDA

What are the most common Tareg adverse events reported to the FDA?

Renal Failure Acute
86 (2.33%)
Fall
60 (1.62%)
Blood Creatinine Increased
59 (1.6%)
Pyrexia
45 (1.22%)
Hyperkalaemia
43 (1.16%)
Asthenia
38 (1.03%)
Malaise
38 (1.03%)
Hyponatraemia
36 (.97%)
Renal Failure
34 (.92%)
Dehydration
33 (.89%)
Hypotension
33 (.89%)
Show More Show More
Drug Interaction
31 (.84%)
General Physical Health Deteriorati...
30 (.81%)
Dyspnoea
27 (.73%)
Hypertension
26 (.7%)
Blood Urea Increased
25 (.68%)
Pruritus
25 (.68%)
Fatigue
24 (.65%)
Pain In Extremity
23 (.62%)
Drug Exposure During Pregnancy
22 (.6%)
Cough
21 (.57%)
Pneumonia
21 (.57%)
Toxic Skin Eruption
21 (.57%)
Dizziness
20 (.54%)
Haemoglobin Decreased
20 (.54%)
Cerebrovascular Accident
19 (.51%)
Condition Aggravated
19 (.51%)
Gait Disturbance
19 (.51%)
Vomiting
19 (.51%)
Arthralgia
18 (.49%)
Aspartate Aminotransferase Increase...
18 (.49%)
Diarrhoea
18 (.49%)
Myalgia
18 (.49%)
Blood Creatine Phosphokinase Increa...
17 (.46%)
Creatinine Renal Clearance Decrease...
17 (.46%)
Rash
17 (.46%)
Rhabdomyolysis
17 (.46%)
Thrombocytopenia
17 (.46%)
C-reactive Protein Increased
16 (.43%)
Confusional State
16 (.43%)
Eosinophilia
16 (.43%)
Inflammation
16 (.43%)
Loss Of Consciousness
16 (.43%)
Atrial Fibrillation
15 (.41%)
Death
15 (.41%)
Nausea
15 (.41%)
Orthostatic Hypotension
15 (.41%)
Surgery
15 (.41%)
Alanine Aminotransferase Increased
14 (.38%)
Anaemia
14 (.38%)
Headache
14 (.38%)
Oligohydramnios
14 (.38%)
Anuria
13 (.35%)
Back Pain
13 (.35%)
Blood Pressure Increased
13 (.35%)
Bradycardia
13 (.35%)
Cytolytic Hepatitis
13 (.35%)
Disturbance In Attention
13 (.35%)
Gastrointestinal Haemorrhage
13 (.35%)
Haematoma
13 (.35%)
Insomnia
13 (.35%)
Lung Disorder
13 (.35%)
Muscle Spasms
13 (.35%)
Syncope
13 (.35%)
Agranulocytosis
12 (.32%)
Cardiac Failure
12 (.32%)
Cholestasis
12 (.32%)
Erythema Multiforme
12 (.32%)
Gamma-glutamyltransferase Increased
12 (.32%)
Oedema Peripheral
12 (.32%)
Skin Lesion
12 (.32%)
Urticaria
12 (.32%)
Visual Impairment
12 (.32%)
Agitation
11 (.3%)
Haematemesis
11 (.3%)
Interstitial Lung Disease
11 (.3%)
Myocardial Infarction
11 (.3%)
Neutropenia
11 (.3%)
Osteoarthritis
11 (.3%)
Overdose
11 (.3%)
Rash Erythematous
11 (.3%)
Rash Maculo-papular
11 (.3%)
Shock
11 (.3%)
Urinary Tract Infection
11 (.3%)
Abdominal Pain
10 (.27%)
Abortion Induced
10 (.27%)
Altered State Of Consciousness
10 (.27%)
Arrhythmia
10 (.27%)
Blood Bilirubin Increased
10 (.27%)
Chest Pain
10 (.27%)
Dermatitis Exfoliative Generalised
10 (.27%)
Erythema
10 (.27%)
Musculoskeletal Stiffness
10 (.27%)
Pneumonitis
10 (.27%)
Septic Shock
10 (.27%)
Anaemia Macrocytic
9 (.24%)
Drug Ineffective
9 (.24%)
Eczema
9 (.24%)
Face Oedema
9 (.24%)
Foetal Growth Retardation
9 (.24%)
Hyperhidrosis
9 (.24%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Tareg, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tareg is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Tareg

What are the most common Tareg adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Tareg, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tareg is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Tareg According to Those Reporting Adverse Events

Why are people taking Tareg, according to those reporting adverse events to the FDA?

Hypertension
533
Drug Use For Unknown Indication
70
Essential Hypertension
27
Product Used For Unknown Indication
16
Cardiac Failure
6
Ill-defined Disorder
6
Show More Show More
Cardiac Disorder
6
Cardiomyopathy
6
Hypertensive Cardiomyopathy
4
Fluid Retention
2
Hypertensive Heart Disease
2
Ischaemic Cardiomyopathy
2
Blood Pressure Increased
2
Myocardial Infarction
2
Atrial Fibrillation
2
Unevaluable Event
2
Pulmonary Arterial Hypertension
1
Prophylaxis
1
Microalbuminuria
1
Aortic Valve Disease
1
Coronary Artery Disease
1

Tareg Case Reports

What Tareg safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Tareg. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Tareg.